Omeros narrowed its quarterly net loss year-over-year, improved cash position through equity raises, and maintained moderate operating expenses ahead of a potentially transformative product launch.

Omeros Corporation significantly improved its financial position in the second quarter of 2025, reducing its net loss to $25.4 million from $56.0 million in the prior year, primarily due to decreased narsoplimab drug substance manufacturing expenses. The company also strengthened its balance sheet by reducing near-term debt and securing new capital, while advancing its key clinical programs, particularly narsoplimab for TA-TMA with an extended PDUFA date.

Omeros Corporation posted a net loss of $33.5 million in Q1 2025 with no reported revenue. The company focused its efforts on advancing the FDA review of narsoplimab and reducing near-term debt obligations through note exchanges and equity conversions.

Omeros Corporation reported a net loss of $31.4 million for the fourth quarter of 2024, an improvement from the $32.2 million net loss in the previous quarter. The company's cash and short-term investments decreased significantly from the prior year, reflecting substantial cost outlays. Key developments include the resubmission of the BLA for narsoplimab and the initiation of a Phase 3 program for zaltenibart.

Omeros Corporation reported a net loss of $37.2 million for the first quarter of 2024. The company received $115.5 million in cash from an amended royalty agreement with DRI Healthcare Acquisitions LP. They are advancing clinical programs for OMS906 and OMS527, and working towards resubmission of the BLA for narsoplimab.

Omeros Corporation reported a net loss of $9.1 million for Q4 2023, compared to a net loss of $37.8 million for the third quarter of 2023. The company's cash used in operations for the fourth quarter was $34.8 million. They received $115.5 million from DRI in February 2024.

Omeros Corporation reported a net loss of $37.8 million for Q3 2023, compared to a net loss of $17.5 million in the prior year quarter. OMIDRIA royalties were $10.0 million, down from $16.5 million in the prior year quarter due to a decrease in the royalty rate. The company had $310.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023.

Omeros Corporation reported a net loss of $37.3 million for the second quarter of 2023. OMIDRIA royalties were $10.7 million. The company is advancing its narsoplimab BLA resubmission for TA-TMA and is on track for Phase 3 data readout from the ARTEMIS-IGAN trial.

Omeros Corporation reported a net loss of $33.7 million for the first quarter of 2023, or $0.54 per share. The company earned OMIDRIA royalties of $9.2 million on Rayner's U.S. net sales of $30.7 million. Omeros received a $200 million milestone payment from Rayner in connection with the Asset Purchase Agreement.

Omeros Corporation reported a net income of $128.7 million, or $2.05 per share, for the fourth quarter of 2022. The company's cash, cash equivalents, and short-term investments totaled $194.9 million. OMIDRIA royalties were $17.9 million on Rayner’s U.S. net sales of $35.8 million.

Omeros Corporation reported a net loss of $17.5 million for the third quarter of 2022. The company earned royalties of $16.5 million on net sales of OMIDRIA and sold an interest in a portion of future OMIDRIA royalty receivables for $125.0 million. The FDA denied the company's appeal regarding the biologics license application for narsoplimab in TA-TMA.

Omeros Corporation reported second quarter 2022 financial results, including royalties of $17.2 million on OMIDRIA sales and a net loss of $30.9 million, or $0.49 per share.

Omeros Corporation reported a net loss of $33.0 million for the first quarter of 2022. The company earned royalties of $13.8 million from Rayner's net sales of OMIDRIA. Omeros had $142.2 million in cash, cash equivalents and short-term investments as of March 31, 2022.

Omeros Corporation reported fourth quarter net income of $280.6 million, which included cash proceeds of $126.0 million from the sale of OMIDRIA. Net revenues from OMIDRIA sales were $31.9 million.

Omeros Corporation reported a net loss of $22.7 million, or $0.36 per share, for the third quarter of 2021. OMIDRIA revenues for the third quarter of 2021 were $30.0 million, a 4.1 percent increase compared to the second quarter.

Omeros Corporation reported financial results for the second quarter ended June 30, 2021. OMIDRIA revenues increased compared to the first quarter. The company's Biologics License Application (BLA) for narsoplimab is under priority review by the U.S. FDA.

Omeros Corporation reported first quarter 2021 financial results, with OMIDRIA revenues at $21.1 million. The company's net loss was $35.1 million, or $0.57 per share. As of March 31, 2021, Omeros had $100.5 million in cash, cash equivalents and short-term investments.

Omeros Corporation reported fourth-quarter revenues of $10.6 million, primarily from OMIDRIA sales, and a net loss of $37.3 million, or $0.60 per share. The company's cash, cash equivalents, and short-term investments available for operations totaled $135.0 million as of December 31, 2020.

Omeros Corporation reported a net loss of $38.5 million for Q3 2020, with revenues of $26.1 million. The revenue decrease compared to Q3 2019 was due to an $8.7 million deduction as a reserve for product returns related to the expiration of pass-through reimbursement on October 1, 2020. The company had $153.5 million in cash, cash equivalents and short-term investments available for operations as of September 30, 2020.

Omeros Corporation reported a decrease in revenue for Q2 2020 to $13.5 million, compared to $26.8 million in Q2 2019. The net loss for the quarter was $33.3 million, or $0.61 per share, compared to a net loss of $14.5 million, or $0.29 per share, for the same period in 2019. The revenue decrease was due to the postponement of cataract procedures due to COVID-19.

Omeros Corporation reported a revenue of $23.5 million for Q1 2020, which is an increase compared to Q1 2019 but a decrease compared to Q4 2019, impacted by COVID-19. The net loss was $29.0 million, or $0.53 per share. The company's cash, cash equivalents, and short-term investments were $54.0 million as of March 31, 2020.

Omeros Corporation reported OMIDRIA revenues of $33.4 million for Q4 2019, representing the highest revenue quarter to date and a 12% increase compared to Q3 2019. The net loss for the quarter was $29.2 million, or $0.58 per share. The company had cash, cash equivalents, and short-term investments of $60.8 million as of December 31, 2019.